I stand corrected. I did not understand this either. However, as...

I stand corrected. I did not understand this either. However, as this is a specifically a P1 safety trial the protocol now makes perfect sense. Dose people up with the drug via IV to get the drug into their plasma, then when drug gets into their urine add the bugs to sampled urine ex vivo. RCE327 kills the bugs in the test-tube and thus presumably also equally well in the bladder. And nobody has to get the UTI infection first. The process puts the drug where an infected person needs it and demonstrably kills the bug in the correct time frame. Voila! Infection ended. This is a good way of doing trials that risks nobody not getting successfully treated for a UTI. Very pertinent in times of COVID. Advances the trial timetable at pace. So what's not to like? Usually safety trials are slow to recruit for and tedious to conduct, and often get interrupted because the drug in question is not proven safe enough for full blown use. This result will give us exactly past that problem I would expect.
The drug can be pumped in at speed - safely and well tolerated. Ditto for gel and other dosage forms. Excellent.
The drug kills bugs at the target site - extremely effectively.
Given the need why would all stops not be being pulled (both by Recce and with encouragement of medical institutions) to expedite Ph2 and 3 trials?
And now cash is in hand to do exactly that.